Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab

Affiliations

¹ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: vannech@live.com.
² Pneumology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
³ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
⁴ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Malaga, Spain.

Case Reports

María Vanessa Chica-Guzmán et al. Ann Allergy Asthma Immunol. 2020 Aug.

. 2020 Aug;125(2):228-230.

doi: 10.1016/j.anai.2020.05.002. Epub 2020 May 11.

¹ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: vannech@live.com.
² Pneumology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
³ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
⁴ Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Malaga, Spain.

No abstract available

Cited by

The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I, Angelopoulos A, Daoussis D. Kouverianos I, et al. Rheumatol Int. 2023 Jul;43(7):1245-1252. doi: 10.1007/s00296-023-05326-1. Epub 2023 Apr 21. Rheumatol Int. 2023. PMID: 37085573 Free PMC article.
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C, Garcia-Olivé I, Urrutia-Royo B, Basagaña-Torrento M, Rosell A, Abad J. Martínez-Rivera C, et al. BMC Pulm Med. 2021 Jan 21;21(1):35. doi: 10.1186/s12890-021-01397-7. BMC Pulm Med. 2021. PMID: 33478439 Free PMC article.
Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O, Minamoto S. Matsuno O, et al. Respir Med Case Rep. 2022 Oct 30;40:101763. doi: 10.1016/j.rmcr.2022.101763. eCollection 2022. Respir Med Case Rep. 2022. PMID: 36353062 Free PMC article.
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y, Aoki-Saito H, Kamide Y, Sato M, Tsurumaki H, Yatomi M, Ishizuka T, Hisada T. Koga Y, et al. Front Pharmacol. 2022 Mar 10;13:865318. doi: 10.3389/fphar.2022.865318. eCollection 2022. Front Pharmacol. 2022. PMID: 35359852 Free PMC article. Review.